Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

NCT03102320 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

173

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Cisplatin
DRUG: Gemcitabine
DRUG: Anetumab ravtansine (BAY94-9343)

Sponsor

Bayer

Collaborators

[object Object]
[object Object]